Rani Therapeutics stock hits 52-week low at 1.29 - Investing.com
RANI Stock | USD 1.39 0.01 0.71% |
Under 57% of Rani Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that many traders are alarmed. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
Rani |
Rani Therapeutics stock hits 52-week low at 1.29 Investing.com
Read at news.google.com
Rani Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
RANI: 1Q:24 Results
recently @ finance.yahoo.com
RANI: 2023 Results
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rani Therapeutics Fundamental Analysis
We analyze Rani Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Rani Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Rani Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rani Therapeutics stock to make a market-neutral strategy. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with similar companies.
Peers
Rani Therapeutics Related Equities
MNPR | Monopar Therapeutics | 9.54 | ||||
GLUE | Monte Rosa | 7.68 | ||||
SRZN | Surrozen | 7.29 | ||||
VIRX | Viracta Therapeutics | 6.67 | ||||
EYPT | Eyepoint Pharmaceuticals | 4.14 | ||||
CRVS | Corvus Pharmaceuticals | 4.13 | ||||
PMVP | Pmv Pharmaceuticals | 1.42 | ||||
TRVI | Trevi Therapeutics | 1.04 | ||||
TNYA | Tenaya Therapeutics | 0.95 | ||||
PHVS | Pharvaris | 0.51 | ||||
TYRA | Tyra Biosciences | 0.41 | ||||
MOLN | Molecular Partners | 0.19 | ||||
TARA | Protara Therapeutics | 0.44 | ||||
BMEA | Biomea Fusion | 1.17 | ||||
CABA | Cabaletta Bio | 1.27 | ||||
VINC | Vincerx Pharma | 3.85 | ||||
LYRA | Lyra Therapeutics | 5.26 | ||||
ALXO | Alx Oncology | 10.27 |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |